Issued: Friday 24 January 2014, London UK - LSE Announcement
GSK receives positive opinion from the CHMP in Europe for once-weekly EperzanTM (albiglutide) for the treatment of type 2 diabetes
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for albiglutide, under the brand name EperzanTM. The CHMP opinion concerns albiglutide proposed as a once-weekly treatment to improve glycaemic control in adult patients with type 2 diabetes mellitus:
|
·
|
As monotherapy, when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to contraindications or intolerance
|
|
·
|
As add-on combination therapy, in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
|
Albiglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an investigational once-weekly type 2 diabetes treatment. GLP-1 is an important incretin hormone that helps normalise blood sugar levels.
"Today's positive opinion is a major milestone towards offering people with uncontrolled type 2 diabetes a new option to help manage their condition and we look forward to the final decision of the European Commission in the coming months", said Dr Carlo Russo, Senior Vice President, Research and Development at GSK. "Diabetes is a global health problem, affecting over 300 million people worldwide. Albiglutide has the potential to help many patients with type 2 diabetes who struggle to control their blood glucose levels."
A CHMP positive opinion is one of the last steps before marketing authorisation is granted by the European Commission. A final decision on marketing authorisation is anticipated during the first quarter of 2014.
Albiglutide is currently undergoing review by other authorities, including the US Food and Drug Administration (FDA) and the US Prescription Drug User Fee Act (PDUFA) target date is 15 April 2014. Albiglutide is not approved for use anywhere in the world.
The CHMP positive opinion is based on an evaluation of a comprehensive global programme of studies involving over 5,000 patients. The programme included eight Phase III trials evaluating albiglutide against commonly-used classes of type 2 diabetes treatment and involved patients at different stages of the disease, as well as those with renal impairment, for up to three years.
In clinical trials, acute pancreatitis has been reported in association with albiglutide and other GLP-1 receptor agonists. The most frequent adverse reactions during clinical trials, which occurred in ≥5% of patients receiving albiglutide, were diarrhoea, nausea, and injection site reactions. If approved, albiglutide will not be appropriate for use in patients with a history of serious hypersensitivity to albiglutide or any of its excipients.
B Kelly-Bisla
Corporate Secretariat
24 January 2014
About albiglutide
Albiglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. GLP-1 is a peptide that is normally secreted from the gastrointestinal tract during a meal which, in turn, helps release insulin to control blood sugar elevations after eating. In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced or absent.
Eperzan is a trademark of the GlaxoSmithKline group of companies.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit http://www.gsk.com/.
|
GSK enquiries:
|
|
|
|
|
UK Media enquiries:
|
David Mawdsley
|
+44 (0) 20 8047 5502
|
(London)
|
| |
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
| |
David Daley
|
+44 (0) 20 8047 5502
|
(London)
|
| |
Catherine Hartley
|
+44 (0) 20 8047 5502
|
(London)
|
| |
|
|
|
|
US Media enquiries:
|
Stephen Rea
|
+1 215 751 4394
|
(Philadelphia)
|
| |
Melinda Stubbee
|
+1 919 483 2510
|
(North Carolina)
|
| |
Mary Anne Rhyne
|
+1 919 483 0492
|
(North Carolina)
|
| |
Emily Beamer
|
+1 215 751 6622
|
(Philadelphia)
|
| |
Jennifer Armstrong
|
+1 215 751 5664
|
(Philadelphia)
|
| |
|
|
|
|
Analyst/Investor enquiries:
|
Sally Jackson
|
+44 (0) 20 8047 5543
|
(London)
|
| |
Kirsty Collins (SRI & CG)
|
+44 (0) 20 8047 5534
|
(London)
|
| |
Tom Curry
|
+ 1 215 751 5419
|
(Philadelphia)
|
| |
Gary Davies
|
+44 (0) 20 8047 5503
|
(London)
|
| |
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
| |
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
| |
Ziba Shamsi
|
+44 (0) 20 8047 3289
|
(London)
|
| |
Lucy Singah
|
+44 (0) 20 8047 2248
|
(London)
|
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.
| |
|
Registered in England & Wales:
No. 3888792
|
| |
| |
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
|
Registered in England & Wales:
No. 3888792
|
| |
| |
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|